**OBJECTIVES**

Hemophilia A and B are lifelong, X-linked recessive disorders that result in a deficiency of clotting factor VIII or factor IX, respectively. There are approximately 16,000 individuals with hemophilia A and 4,000 with hemophilia B in the U.S. Approximately 70% of all people with hemophilia have an inherited gene mutation, while the remaining 30% of cases are caused by a spontaneous mutation. Hemophilia genotype provides meaningful information about bleeding severity, inhibitor risk, carrier detection and prenatal diagnosis. With only 20% of U.S. patients with hemophilia having received genotype analysis, the U.S. lags behind other developed nations. A multi-sector collaboration, known as My Life, Our Future (MLOF), was formed to launch a program addressing this need, while also establishing a repository of associated samples and data to support future scientific discovery and treatment advances in hemophilia.

**METHODOLOGY**

MLOF offers free genotype analysis to patients with hemophilia A or B, and has created a research repository of blood samples and genetic data that could be matched to phenotypic data collected separately. The program is a formal collaboration among four healthcare entities, with representation on a steering committee that guides the program:

- American Thrombosis and Hemostasis Network (ATHN) – working with 135+ affiliated hemophilia treatment centers (HTCs), provides HTC provider education and secure infrastructure for data collection
- National Hemophilia Foundation (NHF) – with 52 chapters, educates consumers and supports recruitment
- Puget Sound Blood Center (PSBC) – central genotyping laboratory and sample repository
- Biogen Idec – scientific collaboration and initiative support

Combining their expertise with the HTCs that deliver genetic services, the partners implemented a pilot program, including a suite of educational materials to support each step of the process with patients and HTCs. (Table 1)

---

**Table 1. Tools to Support Program Implementation**

<table>
<thead>
<tr>
<th>Process Goal</th>
<th>Support Mechanisms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient awareness</td>
<td>NHF Annual Meeting presentations, brochure, video, exhibit; HemAware article; local NHF chapter presentations; <a href="http://www.MyLifeOurFuture.org">www.MyLifeOurFuture.org</a> (includes FAQ, resource center, list of participating HTCs)</td>
</tr>
<tr>
<td>HTC recruitment</td>
<td>ATHN Data Summit presentations, breakout groups, exhibit; interest form and participation agreement; ATHNReport articles; start-up webinars; Biogen Idec Medical Science Liaisons</td>
</tr>
<tr>
<td>Patient enrollment</td>
<td>IRB-approved recruitment materials (brochure, fliers, letters to patients, phone script); HTC contact with patients during comprehensive care visits</td>
</tr>
<tr>
<td>HTC implementation support</td>
<td>HTC implementation webinars, PSBC 1-on-1 clinical research associate support, PSBC lab interpretation report, ATHN Clinical Manager system technical assistance</td>
</tr>
<tr>
<td>Research repository</td>
<td>PSBC sample storage, ATHN data stewardship</td>
</tr>
<tr>
<td>Dissemination of findings</td>
<td>Posters at professional meetings (e.g., APHA, APHL), ATHN research review process, presentations at community events (e.g., chapter annual meetings)</td>
</tr>
</tbody>
</table>
RESULTS

Following the successful pilot with 11 HTCs, MLOF was open to all 137. As of September 30, 2014:

- 40 HTCs have enrolled 1,442 patients into the project. (Figure 1)
- After the initial start-up phase, HTCs have recruited an average of 4-5 patients per HTC per month
- Batch processing of the samples is done in increments of 192, so reports are typically returned to HTCs in 2-3 months. To date, clinical genotyping reports have been sent to providers for 952 patients (66% of samples collected)
- For patients who consent to contribute to research, genetic mutation findings are deposited in the data repository and samples are stored for future scientific study
- 81% of total enrolled patients consented to research (1,168 repository patients)

This project can serve as a model for providing genetic information to patients and creating a resource for scientific investigation in other rare diseases.

Of the 1,442 patients who received genotyping through one of 40 HTCs, 1,151 (80%) had hemophilia A and 291 (20%) had hemophilia B. Demographic breakdown by sex and hemophilia severity is shown in Table 2. The vast majority of those tested were male and about half had severe disease.

Most frequent mutation type was missense: 46% in hemophilia A, 77% in hemophilia B. In patients with severe hemophilia A, 42% were due to inversion 22 or 1 mutations. By comparison to available hemophilia A and B databases, 109 mutations not previously reported were identified in 114 patients. (Figure 2)

CONCLUSIONS

Through collaboration, the partners are providing all U.S. hemophilia A and B patients access to free genotype testing through participating HTCs, and building a data and bio-repository to support future research. This project can inform other rare disorders by providing a model for the collection of genetic information to further research.

REFERENCES